EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Effectiveness and safety of mirikizumab in multirefractory ulcerative colitis: analysis from a real-world cohort

Laura Melotti, Ottavia Monicelli, Nikolas Konstantine Dussias, Veronica Pardi, Vipul Jairath, Marianne Hupé, Marco Salice, Hana Privitera Hrustemovic, Paolo Gionchetti, Fernando Rizzello

Digestive and Liver Disease · 2026-09 · 58 (9) · 1165-1172

DOI: 10.1016/j.dld.2026.06.007 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2026-09. Verfasst von Laura Melotti und 9 weiteren Autor:innen. Beteiligte Einrichtung: IBD Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: laura.melotti@aosp.bo.it. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansFemaleMaleAdultMiddle AgedTreatment OutcomeRemission InductionSeverity of Illness IndexLogistic Models

Stichwörter der Autor:innen

MirikizumabMultirefractoryReal-worldUlcerative colitis

Substanzen

mirikizumabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • IBD Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: laura.melotti@aosp.bo.it.
  • Department of Medical and Surgical and Sciences, University of Bologna, Bologna, Italy.
  • Università di Pisa, U.O. Gastroenterologia Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Department of Medicine,Western University, Ontario, Canada; Department of Epidemiology and Biostatistics,Western University, Ontario, Canada.
  • Division of Gastroenterology, Western University, London, Ontario, Canada.
  • IBD Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Zitieren

APA

Melotti, L., Monicelli, O., Dussias, N. K., Pardi, V., Jairath, V., Hupé, M., Salice, M., Privitera Hrustemovic, H., Gionchetti, P., & Rizzello, F. (2026). Effectiveness and safety of mirikizumab in multirefractory ulcerative colitis: analysis from a real-world cohort. Digestive and Liver Disease, 58(9), 1165-1172. https://doi.org/10.1016/j.dld.2026.06.007

Vancouver

Melotti L, Monicelli O, Dussias NK, Pardi V, Jairath V, Hupé M, et al. Effectiveness and safety of mirikizumab in multirefractory ulcerative colitis: analysis from a real-world cohort. Digestive and Liver Disease. 2026;58(9):1165-1172. doi:10.1016/j.dld.2026.06.007

BibTeX
@article{Melotti2026,
  author = {Melotti, Laura and Monicelli, Ottavia and Dussias, Nikolas Konstantine and Pardi, Veronica and Jairath, Vipul and Hupé, Marianne and Salice, Marco and Privitera Hrustemovic, Hana and Gionchetti, Paolo and Rizzello, Fernando},
  title = {Effectiveness and safety of mirikizumab in multirefractory ulcerative colitis: analysis from a real-world cohort},
  journal = {Digestive and Liver Disease},
  year = {2026},
  volume = {58},
  number = {9},
  pages = {1165--1172},
  doi = {10.1016/j.dld.2026.06.007}
}
Kostenlos starten →